Dose Escalation Trial of Traditional Chinese Medicine for Irritable Bowel Syndrome (TCM- IBS) (TCM-IBS)
2022年2月25日 更新者:Brian Berman、University of Maryland, Baltimore
Dose Escalation Trial Of Traditional Chinese Medicine For Irritable Bowel Syndrome
The purpose of this study is to determine whether a 20- herb formulation, as a well characterised extract, is efficacious in treating irritable bowel syndrome (IBS) and also to identify efficacious and safe dosage of the formulation in treating IBS.
研究概览
地位
地位
完全的
干预/治疗
干预/治疗
详细说明
The Specific aims of the project are:
- To determine whether a 20- herb formulation improves pain/ discomfort and disturbed bowel frequency in patients with Irritable Bowel Syndrome who have been disappointed with current conventional Western medicine.
- To identify an optimal dosage of the 20- herb formulation that is safe and well tolerated for up to 8 weeks of treatment, among 2 dosages. This is determined by relief of symptoms of IBS in a dose escalation, placebo-controlled double- blind randomized clinical trial, in conjunction with indices of safety and tolerability.
研究类型
研究类型
介入性
注册 (实际的)
注册
104
阶段
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Shatin、香港
- Medical Gastroenterelogy Clinic Of the Prince Of Wales, Chinese University of Hong Kong
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
资格标准
适合学习的年龄
18年 至 75年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Age 18- 75
- All IBS patients attending the Gastroenterology Clinic of the Prince Of Wales Hospital of Hong Kong.
IBS diagnosed by Rome III criteria:
- Recurrent abdominal pain or discomfort at least three days per month in the previous three months
- Symptoms onset at least six months prior to diagnose
Pain or discomfort associated with two or more of the following:
- Improvement with defecation
- Onset associated with change in frequency of stool
- Onset associated with a change in form (appearance) of stool
- Normal colonic evaluation (colonoscopy or barium enema) in past 5 years
- No "global symptom improvement" as rated by patients (see below) at screening and during the two- week run- in period to baseline
Normal full blood count, liver function test and renal function test.
- Informed written consent for participation into study.
- Ethical approval will be obtained from the Joint CUHK-NTEC Clinical Research Ethics Committee as well as the IRB of UMB.
Exclusion Criteria:
- Past or present history of organic disease of gastrointestinal tract (e.g. colorectal cancer, advanced colonic polyp, celiac disease, inflammatory bowel disease, peptic ulcer and previous gastrointestinal surgery). (Note: those with polyps removed during colonoscopy can be included, as long as no known polyps remained.
- Systemic diseases that cause diarrhea or constipation (e.g. thyroid disease, diabetic neuropathy)
- Lactose intolerance
- Severe liver disease (e.g. cirrhosis, chronic active hepatitis)
- Renal impairment (serum creatinine level > 150mmol/L)
- Women who are pregnant, lactating or not practicing proper contraception
- Known hypersensitivity to herbal medicine
- Concommitant use of prescription antidepressant medication
- Current alcoholism and drug use
- Current psychiatric illness or dementia
- Fever or severe illness at baseline (week 0).
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
手臂数量
2
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
有源比较器:20-herb formulation
Active herb
|
Two daily dosages will be investigated.
The lowest dosage condition will be 17gm daily, followed by an escalation to 34gm.
Participants will be treated for 8 weeks
|
|
安慰剂比较:Placebo
Placebo herb formulation
|
Placebo herb formulation
|
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Global IBS symptom improvement
大体时间:8 weeks
|
The primary endpoint for this study is the efficacy at the 8 week followup visit of the herbal formulations, which is defined by the patient's global assessment of the IBS symptoms.
|
8 weeks
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The Bowel Symptom Scale (BSS):
大体时间:8 weeks
|
The Bowel Symptom Scale will be used to assess changes in individual IBS and global IBS symptoms during the course of illness.
|
8 weeks
|
|
SF-36
大体时间:8 weeks
|
Quality of Life generic (SF-36), will be used for assessment of quality of life in response to treatment.
|
8 weeks
|
|
IBS-QoL
大体时间:8 weeks
|
Disease-specific (IBS-QoL) will be used for assessment of quality of life in response to treatment.
|
8 weeks
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
合作者
合作者
调查人员
调查人员
- 首席研究员:Brian M Berman, MD、University of Maryland
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
学习开始
2008年5月1日
初级完成 (实际的)
初级完成
2011年3月1日
研究完成 (实际的)
研究完成
2011年6月1日
研究注册日期
首次提交
首次提交
2010年3月28日
首先提交符合 QC 标准的
首先提交符合 QC 标准的
2017年10月2日
首次发布 (实际的)
首次发布
2017年10月4日
研究记录更新
最后更新发布 (实际的)
最后更新发布
2022年3月14日
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
2022年2月25日
最后验证
最后验证
2022年2月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.